Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AVROBIO, Inc.
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.
- Drug Delivery
In Vitro Diagnostics
- Therapeutic Drug Monitoring
- Gene Therapy, Cell Therapy
- Large Molecule